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OBESITY, INTERGENERATIONAL PROGRAMMING, AND EPIGENETICS: 
 EMERGING CONCEPTS AND CHALLENGES 
MICHAEL YUNG-RAY CHEN 
 
ABSTRACT 
 
One of the most important medical and public health issues of today is 
obesity, defined as abnormal and excess fat accumulation. Obesity is linked to 
many health problems including metabolic syndrome (MS), hypertension, type II 
diabetes mellitus (T2DM), and cardiovascular disease (CVD). Recently, the 
incidence of these conditions has surged to epidemic proportions, especially in 
Western societies. Research has also linked obesity to cancer and osteoarthritis. 
Preventing, diagnosing, and treating obesity is challenging. The diagnosis 
of obesity is often unclear when it is made with generalized criteria such as the 
Body Mass Index (BMI). Obesity interventions generally include the often difficult 
lifestyle change to healthy diets and adequate exercise, which depends heavily 
upon patient compliance and discipline.  
Today’s society is pushing for the discovery of a shortcut or of a “magic 
pill” to cure obesity. Consequently, many studies aim to identify therapeutic 
targets. The majority of current obesity research is focused on discovering and 
revealing the underlying mechanisms and genetic risk factors. Certain stages of 
development, such as childhood, are especially susceptible times to be exposed 
to stressors that lead to obesity.  
  vi
A developing concept is the intergenerational transmission of risk of 
obesity through epigenetics. Epigenetics is the study of the heritable changes in 
gene regulation and expression not caused by mutations or changes in DNA 
sequence. A person’s genes may increase or decrease his or her susceptibility to 
obesity. In addition to genetic inheritance, parents may pass non-genetic 
alterations to their children. Changes can be mediated through methylation of 
deoxyribonucleic acids (DNA) and modifications to histones. These epigenetic 
changes may alter gene expression patterns and “program” offspring towards 
developing chronic metabolic disease. Many models have begun to show the 
effects of environmental perturbations on individuals and on several generations 
of future descendants.  
This review will analyze the current literature on obesity and evaluate this 
rapidly evolving field. Current obesity preventions and treatments will be 
surveyed. In addition, the relative impact of different contributors to obesity risk 
will be examined. The crossover between obesity and epigenetics may provide a 
deeper understanding of disease risk and developmental origins. Future 
directions of study will be proposed such as large-scale prospective studies to 
further characterize intergenerational transmission of risk.  
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INTRODUCTION 
 
 
 
 
Famine and food shortages have challenged almost every generation until 
recently. Agricultural and industrial advances in technology have allowed surplus 
amounts of food to be produced around the world. Unfortunately, a lot of this food 
contains high amounts of calories and saturated fats. The increase in 
accessibility of food with high amounts of calories and saturated fat has led to 
eating habits also known as “The Western Diet” (Cordain et al., 2005). Modern 
society now faces a new form of malnourishment; unhealthy eating and reduced 
physical activity have resulted in overweight and obese populations (Caballero, 
2007).  
Obesity is defined by the World Health Organization (WHO) as abnormal 
or excessive fat accumulation that negatively impacts health (WHO, Health 
Topics, Obesity). Obesity occurs when caloric intake exceeds energy 
expenditure (Khandekar et al., 2011). Both genders and all age groups are 
affected by obesity, although it is more common in women and in people of older 
age. Obesity is also more prevalent in developed countries with high median 
incomes. Paradoxically, within these rich countries, obesity disproportionally 
affects the poor  (WHO, Health Topics, Obesity). 
The prevalence of obesity worldwide has risen dramatically from 1980 to 
2008. The percentage of obese men worldwide has gone from 5% to 10% and 
 the percentage of obese women worldwide has gone from 8% to 14%
almost 1.5 billion adults worldwide were 
In the United States, more than two third
obese or overweight. Although this number has been rising for the past few of 
decades, recent data suggests that the incidence of obesity in children is leveling 
off (Flegal et al., 2012). 
Control and Prevention (CDC) and illustrates the massive increase in percentage 
of obese individuals living 
rapid increase underscores the 
 
Figure 1. Obesity trends among U.S. a
about 30 lbs. overweight for 5’4” person
and Statistics). 
  
2 
obese. (WHO, Health Topics, Obesity). 
s of the population is considered 
Figure 1 depicts data collected by the Center for Disease 
in the United States over the past twenty years. This 
seriousness of this public health crisis.
dults. 1990, 2000, 2010. BMI 
. (CDC, Overweight and Obesity, 
. In 2008, 
 
 
 
≥ 30, or 
Data 
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 The traditional method of measuring obesity in adults is the Body Mass 
Index (BMI). A BMI is calculated by dividing the person’s weight in kilograms by 
the square of the person’s height in meters. The normal (healthy) range for an 
adult BMI is between 18.5 and 25. A BMI of 25 or more is considered overweight, 
a BMI of 30 or more is considered obese, and a BMI of 40 or more is considered 
morbidly obese. In children, different BMI cut offs are used. A child’s height and 
weight is plotted on a growth chart for his or her age and sex to obtain a 
percentile. A BMI percentile of 85-95% is considered “overweight” and a BMI 
percentile greater than 95% is considered “obese.” (CDC, Healthy Weight, BMI). 
 Excess weight increases a person’s BMI and is thus considered a 
reflection of a person’s increased adiposity. An increase in adiposity may 
contribute to an increased risk of obesity and other health problems. Although 
early research suggested that overweight BMIs did not detrimentally affect 
mortality, these studies were often poorly controlled because they included 
patients that smoked or who had disease related weight loss (Berrington de 
Gonzalez et al., 2010). These studies also had large age distributions or small 
sample sizes. Pooled prospective studies have recently shown that, when 
controlled for confounders, BMI is associated with all-cause mortality in 
Caucasians (Berrington de Gonzalez et al., 2010). Similar findings have also 
been established in Asian populations (Chen et al., 2012).   
 The BMI is often criticized as inaccurate or misleading in terms of 
adiposity. Much debate exists about the usefulness of BMI due to the simplicity of 
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its formula (Ahima and Lazar, 2013). BMI may be appropriate for use in 
population studies, but may be inappropriate for use in diagnosing individual 
patients. Differences in ethnicity, gender, age, fat percentage, and fat distribution 
are not taken into consideration.  
 The amount of muscle mass a person has affects their weight and BMI. 
Athletes and those with a lot of muscle will have higher BMIs that overestimate 
body fat. Older people and those with less muscle will have lower BMIs that may 
underestimate body fat. 
 Ethnicity also affects obesity. People of African descent typically have 
higher BMIs, but relatively few health problems. In contrast, people of Asian and 
Hispanic descent are often more susceptible to obesity and many develop 
obesity related complications at lower BMIs. Consequently, several international 
health organizations, predominately in Asia, have established lower thresholds 
for being considered overweight and obese. (WHO, Health Topics, Obesity). 
 Recently, there has been increased recognition of a unique subgroup of 
obese and overweight individuals that have metabolically normal phenotypes, 
termed “metabolically healthy obese” (MHO). MHO patients have increased 
adiposity compared to non-MHO patients, but the increased adiposity does not 
seem to be detrimental to their health (Karelis et al., 2005). In addition, some 
obese patients with diabetes, end stage renal disease, and hypertension have 
surprisingly been shown to have reduced mortality compared to normal weight 
individuals. In contrast, a different subgroup of normal weight individuals has 
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been shown to have poor metabolic status. These populations may seem 
paradoxical at first, but studies continue to demonstrate that obese individuals 
have a higher risk of adverse outcomes when compared to normal weight 
individuals. A recent study analyzed the results from two large prospective 
cohorts and concluded that the data refuted the notion of lower mortality or better 
health in obese patients. (Tobias et al., 2014).   
 It is hypothesized that the studies with the paradoxical populations may 
have failed to establish controls properly (Kramer et al, 2013). Normal 
populations may have been classified solely based on BMI without considering 
other metabolic parameters. Additionally, smoking substantially increases 
cardiovascular risk and is a likely confounder. Better experimental controls 
should include both BMI and metabolism measurements. When comparing 
obese individuals without metabolic complications to normal weight individuals 
without metabolic complications, obese individuals still have a higher risk for 
death, CVD, and cancer (Kramer et al, 2013). This suggests that BMI is, at the 
very least, a good indicator of health. 
The American Medical Association (AMA) did not officially begin to 
recognize obesity as a disease until June 2013 (AMA, June 18, 2013 Press 
Release). The AMA is the largest organization of physicians and medical 
students in the United States. Although the decision to recognize obesity as a 
disease was not without controversy, it is hoped that the decision will bring more 
attention and resources to the disease.  
 6 
SPECIFIC AIMS 
 
 
 
Obesity is an epidemic in the United States and around the world. Its 
associated comorbidities are detrimental to health and life expectancy. Studies 
continue to correlate more and more maladies every year to obesity.  
It has been challenging to pinpoint the exact cause of obesity. There are 
many elements that influence susceptibility to obesity and the relative impact of 
each is unknown. Elements that may contribute to obesity include genetics, 
environment, and intergenerational programming. 
The goal of this review is to perform a systematic analysis of current 
literature and the assess factors that may contribute to obesity. The emerging 
concepts of intergenerational transmission of risk and epigenetics will be 
discussed in detail. 
It is hoped that this report will identify the elements that increase or 
decrease a person’s likelihood of developing obesity. If human intervention and 
control is a factor, then ways to reduce the incidence of obesity will be proposed. 
Suggestions for future directions of study in the field of obesity will also be made. 
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ASSOCIATED HEALTH RISKS 
 
 
 
 Obesity is associated with many health risks.  Common health risks 
among obese individuals are metabolic syndrome (MS), type II diabetes mellitus 
(T2DM), cardiovascular disease (CVD), and cancer. Many of these comorbidities 
are also among the leading causes of death in the United States (CDC, National 
Center for Health Statistics).  
 
Metabolic Syndrome 
Metabolic syndrome (MS), also known as Syndrome X, is the name for a 
group of risk factors that increases one’s risk for developing health problems 
such as heart disease, diabetes, and stroke. The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel III (ATPIII) stipulates that a diagnosis of 
MS is appropriate if a patient has at least three of the following five metabolic risk 
factors: large waistline, high triglyceride level, low high-density lipoprotein (HDL) 
cholesterol level, hypertension, and high fasting blood sugar (Grundy et al., 
2005). The specific categorical cutpoints for MS are listed in Table 1. The 
chances of developing MS are associated with being overweight or obese, being 
older, having an inactive lifestyle, having insulin resistance, and having a genetic 
predisposition (NIH, Metabolic Syndrome). 
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Table 1. Criteria for clinical diagnosis of metabolic syndrome. NCEP/ATPIII 
guidelines last updates by the NHLBI and AHA in 2005. (Adapted from Grundy et 
al., 2005). 
 
RISK FACTOR CATEGORICAL CUTPOINTS 
Large waist circumference ≥ 102 cm (≥ 40 inches) in men 
≥ 88 cm (≥ 35 inches) in women 
High triglycerides 
≥ 150 mg/dL 
or 
On drug treatment for elevated triglycerides 
Low HDL cholesterol 
< 40 mg/dL in men 
< 50 mg/dL in women 
or 
On drug treatment for reduced HDL 
High blood pressure 
≥ 130 mm Hg systolic blood pressure 
or 
≥ 85 mm Hg diastolic blood pressure 
or 
On antihypertensive drug treatment in a patient with 
a history of hypertension 
High fasting blood sugar 
≥ 100 mg/dL 
or 
On drug treatment for elevated blood sugar 
 
 
The diagnosis of MS is controversial. A person who has MS has a higher 
risk for developing CVD and T2DM. However, the presence of even one risk 
factor raises a person’s risk for developing disease. The more metabolic risk 
factors a patient has, the more likely he or she is to develop obesity related 
diseases. The diagnostic utility is unclear because it is uncertain whether having 
the full syndrome is more risky than having each of the criteria (Beltran-Sanchez 
et al., 2013). 
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In the United States, approximately 22% of the population has MS 
(Beltran-Sanchez et al., 2013). It does not affect all sexes, races, and ethnic 
groups equally. For example, Mexican Americans have the highest rate of MS 
followed by Caucasians and then African Americans. A higher percentage of 
female Mexican Americans and African Americans have MS than male Mexican 
Americans and African Americans. By contrast, an equal percentage of 
Caucasian females and males have MS. (Beltran-Sanchez et al., 2013). 
 
Diabetes 
 Diabetes mellitus is a metabolism disorder characterized by a very high 
blood sugar level. In the United States, almost 8% of the population has 
diabetes. Rates of diabetes have been projected to reach much higher levels 
over the next several decades with escalation of the obesity epidemic (NIDDK, 
Diabetes Overview). Diabetes is one of the leading causes of death and 
disability. It is estimated to be responsible for almost $175 billion each year in 
medical costs, reduced productivity, lost time from work, and disability payments 
(NIDDK, Diabetes Overview).  
Diabetes is diagnosed with a blood glucose test. A patient has diabetes if 
his or her blood glucose level is 200 mg/dL or higher and he or she has 
symptoms of diabetes, his or her fasting blood glucose level is 126 mg/dL or 
higher, or if his or her blood glucose level is 200 mg/dL or higher after an oral 
glucose tolerance test. (NIDDK, Diabetes Overview). 
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 It is important for glucose to be absorbed by the cells because it is the 
body’s main source of energy. Carbohydrates are broken down after they are 
eaten and digested into simple sugars such as glucose. The glucose is readily 
absorbed into the bloodstream by the gut. In non-diabetics, the pancreas 
produces insulin in response to ingestion in order to move glucose from the blood 
into systemic cells. In people with diabetes, the pancreas produces no insulin, it 
does not produce enough, or the cells do not appropriately respond to the insulin. 
(NIDDK, Diabetes Overview). 
 There are three main types of diabetes – type 1 diabetes mellitus (T1DM), 
type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM).  
 T1DM affects approximately 5-10% of the population with diabetes in the 
United States, but overall only affects 0.5% of the total population. In T1DM, the 
immune system attacks and destroys the pancreas’ insulin-producing beta cells. 
Since the pancreas is unable to produce adequate insulin, patients with T1DM 
must take insulin injections. Failure to treat will cause ketoacidosis and ultimately 
death. Symptoms usually develop relatively quickly and include increased thirst, 
increased urination, constant hunger, weight loss, blurred vision, and extreme 
fatigue. T1DM is most common in children, young adults, and Caucasians. 
(NIDDK, Diabetes Overview). 
 The majority of diabetics in the United States have T2DM. T2DM is 
characterized by insulin resistance because, although the pancreas produces 
insulin, the body is unable to use the insulin effectively. Insulin resistance is the 
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result of disruptions in the cell signaling of insulin, the insulin receptor, or 
downstream pathways of insulin. Symptoms may develop slowly and include 
fatigue, frequent urination, increased thirst, increased hunger, weight loss, 
blurred vision, and slow healing of wounds. Similar to T1DM, long term 
complications in T2DM include CVD, renal failure, retinopathy, and edema. 
T2DM is common in people who are overweight or obese, older, physically 
inactive, have a family history of diabetes, or had GDM during pregnancy. 
Certain ethnicities are more likely to have T2DM, including African Americans, 
American Indians, Asian Americans, Native Hawaiians, Pacific Islander 
Americans, and Hispanics. (NIDDK, Diabetes Overview). 
 Interestingly, a small percentage of adults who have T2DM exhibit the 
“obesity paradox.” This refers to the observation that normal weight adults have a 
higher mortality than overweight and moderately obese adults. Although there is 
a well-established positive correlation between BMI and many chronic conditions, 
studies have shown that normal weight adults with T2DM have a higher mortality 
than heavier adults with T2DM (Carnethon et al., 2012). Many people who have 
extremely poor diabetes control lose weight because they lose so much glucose 
in their urine. Glucose is normally completely reabsorbed in the kidneys, but the 
kidneys are not able to handle extremely high levels of glucose. Consequently, 
excess glucose is not reabsorbed by the kidney and is excreted through the 
urine. Other theories suggest that the paradox is the result of inflammation, body 
fat distribution, or adipose tissue action. (Carnethon et al., 2012). 
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Around 3-8% of the population of pregnant women in the United States 
develops GDM (NIDDK, Diabetes Overview). Higher maternal BMI is strongly 
associated with higher risk for GDM (Chu et al., 2007).  GDM is caused by 
pregnancy hormones that trigger insulin resistance or by a shortage of insulin. 
Usually GDM goes away after the woman delivers the baby. However, women 
with prior GDM have a high risk of developing T2DM. Certain ethnic groups and 
women with a family history of diabetes are more likely to develop gestational 
diabetes. (NIDDK, Diabetes Overview). 
 Diabetes increases risk of CVD. Many conditions and risks are shared 
between the two diseases. It is important for people with diabetes to reduce 
cardiovascular risk factors such as diet, smoking, high cholesterol, and blood 
pressure. More than 65% of those with diabetes die from heart disease or stroke. 
(NIDDK, Diabetes Overview). 
 
Cardiovascular Disease 
 CVD is the leading cause of death in the United States. Obesity related 
CVD includes myocardial infarction, coronary artery disease (CAD), angina, 
aortic aneurysm and dissection, arrhythmias, atrial fibrillation, cardiomyopathy, 
heart failure, and peripheral artery disease. (CDC, Heart Disease). 
The most common type of cardiovascular disease is CAD. This occurs 
when cholesterol deposits build up in the arteries that supply blood to the heart, 
causing atherosclerosis. If the heart muscle does not get enough blood, then 
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angina may result. Prolonged CAD weakens the heart and makes a patient more 
susceptible to heart failure and arrhythmias. (CDC, Coronary Artery Disease). 
The diagnosis of CAD is made by evaluating a patient’s blood pressure, 
cholesterol, blood sugar, and family history of heart disease. Electrocardiograms 
(EKG), echocardiograms, exercise stress tests, chest x-rays, cardiac 
catheterizations, and coronary angiograms may also be performed. (CDC, CAD). 
Extreme obesity is associated with CVD and heart failure. It was thought 
that these correlations were indirectly related to each other through covariates 
such as dyslipidemia (abnormal lipid and cholesterol levels), hypertension, high 
blood sugars, and T2DM. However, recent studies have shown that increased 
BMI is directly associated to increased risk of heart failure independent of other 
factors. Not only is this true for the morbidly obese, but it is also true for people in 
all BMI categories. There is no threshold for association; risk for CVD increases 
with higher BMI. (Kenchaiah et al., 2005). 
 
Cancer 
 Cancer occurs when abnormal cells grow out of control due to DNA 
damage. There are more than a hundred different types of cancer. Half of all 
males and a third of all females in the United States will develop at least one 
cancer during their lifetimes (ACS, Cancer Basics). The NIH estimates that 
cancer costs over $200 billion every year (NIH, Cancer). 
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 Obese individuals have an increased risk of developing certain types of 
cancer including: esophagus, pancreas, colon/rectum, post menopause breast, 
endometrium, kidney, thyroid, and gallbladder. In 2007, it was estimated that 4% 
of new cancers in men and 7% of new cancers in women were due to obesity 
(NCI, Obesity and Cancer Risk). In fact, 40% of new endometrial and esophageal 
cancers are due to obesity alone (NCI, Obesity and Cancer Risk). 
 Increased BMI is correlated to increased death rate from all cancers 
combined. Studies estimate that in 2000 in the United States, 14% of all cancer 
deaths were attributable to overweight and obese men and 20% of all cancer 
deaths were attributable to overweight and obese women (Calle and Thun, 
2004).  
It is hypothesized that obesity and cancer are linked for several reasons. 
Fat tissue is known to produce excess estrogen and high levels of estrogen are 
associated with breast and endometrial cancers (Calle and Thun, 2004). Fat is 
also known to produce leptin, which may promote cell proliferation (Choi et al., 
2005). Adiponectin, which is reduced in obese people, has been suggested to 
inhibit tumorgenesis (Khandekar et al., 2011). Fat cells may affect tumor growth 
regulators. Hyperinsulinemia and hyperlipidemia may promote the development 
of certain types of tumors. Chronic low-level inflammation due to macrophage 
infiltration, which is common in adipose tissue, is associated with increased 
cancer risk. (NCI, Obesity and Cancer Risk; Calle and Thun, 2004). 
 
 15 
Osteoarthritis 
 Arthritis is inflammation of the joints. Common types of arthritis include 
osteoarthritis, rheumatoid arthritis, and juvenile arthritis. Osteoarthritis is the most 
prevalent type of arthritis afflicting around 27 million people in the United States 
(NIH, Osteoarthritis; AF, Osteoarthritis).  
Osteoarthritis occurs when the cartilage that normally cushions bones 
breaks down and wears away. This causes bones to rub against each other. 
Eventually the joint may change shape or may grow small bone deposits.  
Broken bone and cartilage may float in the joint space. This results in pain, 
swelling, and loss of movement in the joint. It is generally a slowly progressing 
disease. The most common body parts affected by osteoarthritis are the finger, 
thumb, neck, lower back, knee, and hip joints. (NIAMS, Osteoarthritis). 
Osteoarthritis is most common in older people and in women (Cross et al., 
2014). Risk factors for osteoarthritis include increasing age, obesity, previous 
joint injury, overuse of joint, weak thigh muscles, and genetics (AF, 
Osteoarthritis). Increased weight harms joints because it puts added pressure on 
them (NIAMS, Osteoarthritis). Recent studies also suggest that osteoarthritis is 
affected by the chronic low-grade inflammation associated with obesity (Griffin 
and Guilak, 2008). 
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PREVENTION/TREATMENT 
 
 
 
 
 There are many established obesity treatments and prevention methods, 
including healthy diets and daily exercise regimens. Other treatments include 
drugs and surgery.  
  
Diet 
The primary obesity prevention and treatment method is following a 
healthy diet such as low-fat and low-calorie diets. It is well established that diet 
affects adiposity and weight. Obese people typically have poor dietary habits and 
consume more calories than they burn (HHS, Physical Activity Guidelines). A 
person’s ideal daily calorie need is calculated by taking into account age, gender, 
and physical activity level.  In order to lose one pound of body fat, a person 
needs to consume 3,500 calories below his or her calorie needs (HHS, Calories). 
In addition to consuming too many calories, unhealthy eating habits that often 
lead to weight gain include eating too quickly, eating when not hungry, eating 
mindlessly, and skipping meals. Poor dietary habits also include eating fast-food 
and drinking sugar-sweetened beverages. (CDC, Eating Habits).  
The United States Department of Agriculture’s (USDA) current nutrition 
guide, called “MyPlate,” debuted on June 2, 2011. The circular plate is divided 
into four sections corresponding to 30% grains, 30% vegetables, 20% fruits, and 
20% proteins. A smaller circle represents one serving of dairy. Additional 
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guidance includes switching to skim or 1% milk, making at least half of your 
grains whole grains, varying protein food choices, and cutting back on foods with 
high levels of solid fat, sugar, and salt. The USDA also recommends being aware 
of your personal daily calorie limit and limiting your intake of alcohol to 1 drink per 
day for women and 2 drinks per day for men. (USDA, MyPlate). 
Saturated fats and trans fats from food have a more negative impact on 
health than unsaturated fats. Solid fats increase low-density lipoprotein (LDL) 
cholesterol levels, triglyceride levels, and promote CVD. Excessive consumption 
of solid fats is also associated with insulin resistance and inflammation. 
Unsaturated fats are not generally associated with such unhealthy 
consequences. (Lottenberg et al., 2012; Rosqvist et al., 2014). 
 In western societies, the Mediterranean diet is highlighted as an ideal 
healthy diet. This diet is based on the foods frequently prepared and consumed 
around the Mediterranean Sea. For example, most of the grains in the 
Mediterranean region are whole grains and bread is usually dipped in olive oil 
(mainly unsaturated fat). This diet features many fruits, vegetables, grains, olive 
oil, beans, nuts, seeds, herbs, and spices. Seafood is a staple eaten a little less 
frequently. Nuts and red wine are consumed in moderation. Red meats, dairy 
and sweets are consumed very infrequently. Studies have shown that adherence 
to a Mediterranean diet is correlated with a decreased likelihood of becoming 
obese (Mendez et al., 2006; Shai et al., 2008).  
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 Other popular diets that have been studied for obesity prevention or 
treatment are low calorie diets and low carbohydrate diets. There are many low 
carbohydrate, high protein, and high fat diet plans such as the Atkins diet. 
Although low carbohydrate diets have been shown to be effective in weight 
reduction in the first 6 months of implementation, there is no significant difference 
compared to other diets after one year (Foster et al., 2003). At the same time, 
low carbohydrate, high protein, and high fat diets have a positive effect on lipid 
metabolism (Shai et al., 2008). 
 
Exercise 
 Physical activity is very important to weight loss because exercise 
consumes energy and results in a negative caloric balance. Sedentary lifestyles 
and activities, such as excessive television watching, are correlated to weight 
gain (Mozaffarian et al., 2011). Insufficient exercise is also linked to co-
morbidities including obesity, pulmonary disease, neurological disorders, and 
immune dysfunction (Handschin and Spiegelman, 2008). Along with diet, 
exercise substantially prevents risk for obesity, T2DM, and CVD (Tuomilehto et 
al., 2001; Stampfer et al., 2000). 
The United States Department of Health and Human Services (HHS) and 
CDC recommends that people get at least 150 minutes of moderate aerobic 
exercise each week. This includes walking briskly, water aerobics, and 
gardening. The equivalent in vigorous aerobic physical activity each week would 
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be 75 minutes. This includes running, swimming, dancing, bicycling, and hiking. 
Additionally, HHS recommends that people do muscle strengthening activities at 
least twice a week such as resistance training and weight lifting. (HHS, Physical 
Activity Guidelines).  
Long-term increases of physical activity and reduction of sedentary activity 
have a positive effect on weight loss (Cote et al., 2013). Exercise programs 
consistent with these guidelines prevent increased adiposity and exercise 
programs in excess of these guidelines result in fat reduction (Slentz et al., 
2005). According to HHS, many people need to do more than 300 minutes of 
moderate-intensity or 150 minutes of vigorous-intensity activity a week in order to 
meet weight control goals (HHS, Physical Activity Guidelines). Increased 
intensity of physical activity has been show to reduce the risk factors of MS and 
CVD (Rennie et al., 2003).  
 
Pharmaceuticals 
 If a patient is not successful in reducing their weight and metabolic risk 
factors with diet and exercise alone, he or she may be prescribed drugs to help. 
Pharmaceuticals are intended as a supplementation to lifestyle changes and not 
as substitutions. Nearly all drugs come with risks and side effects that need to be 
balanced with the potential benefits.  
In the United States, the Food and Drug Administration (FDA) is the 
agency that controls pharmaceutical regulation. Currently, there are only three 
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long-term drugs approved by the FDA to treat obesity and weight control: orlistat, 
loraserin, and phentermine-topiramate (NIDDK, Prescription Medications). 
 Orlistat is sold both as a prescription drug (Xenical) as well as an over the 
counter drug (Alli). As a lipase inhibitor, it prevents digestive enzymes from 
breaking down dietary fat, thereby decreasing absorption of fat from food. Most 
patients lose 3 to 5 pounds per year on Alli or 5 to 7 pounds per year on Xenical. 
Since a lot of fat is undigested, complications include abdominal pain, flatulence, 
loose stool, and diarrhea. It is recommended that no more than 30% of the 
calories that patients consume while taking orlistat are from fat. It is highly 
recommended that patients taking orlistat also take a multivitamin supplement 
because of the decrease in absorption of fat-soluble vitamins from food. (NIDDK, 
Prescription Medications). 
Lorcaserin (Belviq) and phentermine-topiramate (Qsymia) were recently 
approved by the FDA in 2012. Lorcaserin acts on serotonin receptors to quickly 
generate satiety. Phentermine is an appetite suppressant and it is combined with 
topiramate, which is an appetite suppressant as well as an antiepileptic. (NIDDK, 
Prescription Medications). 
Both lorcaserin and phentermine-topiramate have side effects, including 
dizziness, dry mouth, and constipation (NIDDK, Prescription Medications). There 
are also risks of adverse tumorigenic, teratogenic, psychiatric and cognitive 
effects (NIDDK, Prescription Medications). Patients may be wary to take either 
drug due to slight risk of adverse cardiac events such as serotoninergic 
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valvulopathy, regurgitation, and valve insufficiency. The FDA has ordered both 
drugs to undergo continued clinical studies to determine strength of associations 
(FDA, Consumer, Medications, Target Long Term Weight Control). Studies have 
not demonstrated that locaserin and phentermine-topiramate have greater 
efficacy than orlistat (Colman et al., 2012). 
 Other weight loss drugs include appetite suppressants such as 
benzphetamine, diethylpropion, phendimetrazine, and phentermine. However, 
these drugs are only approved by the FDA for short term use due to potential for 
abuse. Side effects range from mild dizziness to serious cardiovascular 
complications.  
Some drugs are used “off-label” to treat obesity. Although not FDA 
approved to treat obesity, metformin, which is approved for T2DM, is used to 
lower blood sugar, high LDL levels, and high triglyceride levels (NIDDK, 
Prescription Medications). Some studies have shown that even in the absence of 
T2DM, metformin reduces weight, which suggests that it may be used to help 
reduce obesity (McDonagh et al., 2012). 
 
Surgery 
 Surgery is the final option for weight loss in obese people. Surgery has 
many potential risks and complications including death, excessive bleeding, 
sepsis, and blood clots (Inge et al., 2014). Therefore, it is only recommended for 
very obese patients who had not had success with diet and exercise alone.  
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 Bariatric surgery changes the digestive system and reduces how much 
can be eaten and reduces the absorption of nutrients. Gastric bypass is the most 
common type of bariatric surgery. Roux-en-Y involves reducing the stomach to 
the size of a walnut and connecting it directly to the middle part of the small 
intestine. Biliopancreatic diversion with duodenal switch consists of removing 
80% of the stomach and connecting the remaining stomach to the end of the 
intestines. During laparoscopic adjustable gastric banding, an inflatable and 
adjustable band is placed at the top of the stomach to limit the stomach’s size. In 
vertical banded gastroplasty, the stomach is stapled to create a small upper 
stomach. Finally, sleeve gastrectomy involves altering the stomach to be shaped 
like a tube. (Mayo Clinic, Gastric Bypass Surgery). 
After bariatric surgery, a special diet and exercise regimen will need to be 
conscientiously followed. This involves very small and frequent healthy meals 
and vitamins because there is a high risk of micronutrient deficiency. There are 
new spatial constraints in the gut and surgery may have removed or decreased 
the efficacy of absorption. (NIH, Weight Loss Surgery). 
Studies have shown that bariatric surgery improves and normalizes 
obesity related comorbidities including CVD, T2DM, cancer, and overall mortality 
(Sjöström, 2013; Adams et al., 2007). The mechanisms of action may extend 
beyond decreases in caloric intake (Laferrere et al., 2008). Recent studies have 
demonstrated that bariatric surgery resulted in improved glycemic control 
compared to traditional medical therapies (Mingrone et al., 2012; Schauer et al., 
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2012).  Also, alterations in gut signaling from incretins, microbiota, and bile salts 
may be potential drivers of weight loss (Patti et al., 2009).  
Lifestyle changes, pharmacotherapy, and surgery offer a wide range of 
treatments for obesity. Lifestyle modifications in diet and exercise should always 
be the first treatment due to accessibility and efficacy. It is important and effective 
to continue following a healthy diet and exercise regiment in addition to any other 
obesity treatment. Progression to more intensive treatments such as drugs and 
surgery involves considering the additional benefits and risks as well as 
qualifications and cost (Kushner, 2014). Surgery, the most invasive intervention, 
continues to be the most effective and long-lasting treatment. 
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GENETICS OF OBESITY 
 
 
Human metabolism is an incredibly complex energy homeostasis. It 
involves the balance of numerous metabolic signaling pathways and systems. 
Healthy individuals generally balance the amount of energy that goes into their 
bodies with the amount of energy that comes out of their bodies. Reducing 
obesity to simply excess energy intake versus energy output may be an 
oversimplification. The complexity of concurrent dysfunctions makes it difficult 
pinpoint a single cause of obesity.  
 Obesity is a relatively recent problem. The thrifty gene hypothesis 
attempts to explain why obesity is so prevalent in modern society (Hales and 
Barker, 2001). The thrifty gene hypothesis proposes that we are genetically 
programmed to conserve energy. The thrifty genotype exhibited positive natural 
selection by numerous generations due to its benefits during famines. When food 
was in abundance, individuals with the thrifty genotype efficiently stored and 
utilized energy by adding fat to their bodies. Individuals with the thrifty genotype 
were evolutionally favored when food was scarce because they were able to rely 
on their stored fat for survival (Hales and Barker, 2001). In today’s society, 
however, food is more abundant. The historical transition from cycles between 
times of feasts and famines to a constant time of excess food rendered the thrifty 
gene no longer beneficial. Without famines, excessive energy translates to 
excessive adiposity and obesity (Hales and Barker, 2001). 
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Some researchers critique the thrifty gene hypothesis because it puts too 
much emphasis on the role of famines in human mortality (Speakman, 2007). 
Natural selection dictates that the stronger genotype survives and the weaker 
genotype dies. Some suggest that famines in the past were not frequent enough 
to cause such a large genetic shift. Otherwise, everyone would be obese 
(Speakman, 2007). 
An alternative to the thrifty gene hypothesis is the drifty gene hypothesis 
(Speakman, 2007). Today’s wide range of phenotypes may be the result of 
genetic drift. The drifty gene hypothesis suggests that after the threat of 
predation by large carnivores was removed, the upper limit of human body 
fatness drifted upwards unbounded because selective pressure to maintain a 
competitive maximum amount of body fatness no longer existed. Individuals with 
poor fitness did not survive the early days of human life. The discovery of fire and 
the invention of weapons released the constraints on obesity (Speakman, 2007). 
The drifty gene hypothesis has been critiqued because it makes illogical 
assumptions about the number of gene mutations, gene mutation functions, and 
population size. The drifty gene hypothesis also fails to explain the extremely 
high prevalence of unfavorable obesity related traits in modern society – much 
higher than simply random mutation. Additionally, it does not factor the effect of 
cognitive dietary restraint to maintain BMI below the natural level or the effect of 
famines on fertility (Prentice et al., 2008). 
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Genetic/Molecular Features 
 Nearly all organ systems and cells in the body affect the molecular and 
genetic features of obesity. Many genes and molecules have a role in 
metabolism and homeostasis. Genetic transmission from parent to offspring 
plays a key role in risk for obesity. Studies on twins and people who were 
adopted indicate that anywhere from 40-70% of variability in body mass may be 
attributed to genetic predisposition (Calle and Kaaks, 2004). 
 Before recent discoveries and completion of the human genome, genetic 
studies on obesity were mostly limited to Mendelian diseases linked to single 
genes (Fall and Ingelsson, 2014). Restriction fragment length polymorphism was 
used to study a single target at a time. Monogenic traits associated with obesity 
were primarily found in deficiencies in appetite regulation such as leptin, leptin 
receptor, pro-opiomelancortin, and melanocortin 4 receptor. New developments 
in genome mapping and DNA sequencing have led to more comprehensive and 
unbiased techniques such as genome wide association studies (GWAS). These 
advances have allowed researchers to scan the entire genome for changes that 
correlate to a specific phenotype, like obesity (Fall and Ingelsson, 2014). 
 The use of GWAS has led to a greater understanding of the genetics of 
obesity. The first single nucleotide polymorphism to be associated with BMI was 
the FTO (fat mass and obesity associated) gene (Fall and Ingelsson, 2014). FTO 
is implicated in the regulation of appetite as well. Subsequently, it has been 
established that numerous specific loci are directly associated with obesity, 
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ranging from appetite regulation to growth factors to glucose homeostasis. 
Obesity is a polygenic disease with genetic variants throughout the body (Fall 
and Ingelsson, 2014). 
 Systemic body regulation is commonly studied in relation to hormone 
control. The most characterized hormones in regard to obesity risk are insulin, 
leptin, adiponectin, ghrelin, and incretins. 
 Insulin has a role in glucose uptake in tissues such as liver, muscle, and 
fat. However, insulin signaling is far more complex than simply glucose uptake. 
Figure 2 is a simplified model depicting the involvement of insulin and its receptor 
in gluconeogenesis, glucose synthesis, protein synthesis, and cell growth and 
differentiation.  
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Figure 2. Critical nodes in the insulin signaling network. (Taniguchi et al., 2006). 
 
 The insulin receptor (IR) is a receptor tyrosine kinase that phosphorylates 
insulin receptor substrates (IRS) that activate two major pathways when insulin is 
bound.  The first activated pathway is the mitogen activated protein kinase 
(MAPK) via Ras. The MAPK family, also known as extracellular signal regulated 
kinases (ERK), are responsible for regulating the cell cycle, growth, 
differentiation, and apoptosis.  The other activated pathway is the 
phosphatidylinositol 3-kinase (PI3K) pathway, which performs the majority of 
insulin’s metabolic activities. All of these proteins have different isoforms; each 
has a different specificity and role in the complex signaling network. (Taniguchi et 
al., 2006). 
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 Insulin signaling also has cell specific roles. All of its specific function in 
each tissue is not yet fully known.  Various roles have been elucidated by 
studying insulin resistance and action in obesity and in tissue-specific IR 
knockout models in mice (Rask-Madsen and Kahn, 2012). Figure 3 shows the 
different physiological features of insulin signaling in obesity and in MS. 
Impairment of insulin signaling leads to insulin resistance, elevated glucose 
levels, dyslipidemia, fat accumulation, inflammation, and impaired appetite 
regulation (Rask-Madsen and Kahn, 2012). 
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Figure 3. Tissue specific action of insulin in a patient with obesity and metabolic 
syndrome. (Rask-Madsen and Kahn, 2012). 
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Tissues 
 Defects in many different types of tissues are linked to obesity. 
Collectively, these defects cause metabolic dysfunction. In order to understand 
the big picture, it is important to examine the impact of each defect. 
 
Adipose Tissue 
Adipose is an endocrine tissue that directly secretes hormones into 
circulation. It allows humans to store energy in the form of fat for future energy 
needs. It plays a central role in energy balance and nutritional homeostasis 
(Rosen and Spiegelman, 2014). Fat tissue is composed of many different cell 
types, but mostly of adipocytes, from which it derives its name.  
In adults, the number of adipocytes generally remains the same with 
constant turnover; an equal number are created and are destroyed each year 
(Spalding et al., 2008). During overnutrition, however, the body needs to store 
excess energy from increased food intake. Overnutrition causes adipose depots 
to expand initially in size by hypertrophy and eventually in number by hyperplasia 
(Rosen and Spiegelman, 2014). Hyperplasia occurs mostly in childhood and 
number of adipocytes becomes set. Even after reduction of weight and BMI, the 
adipocyte number remains fairly constant. Consequently, adipocyte number 
gained in childhood becomes a major determinant of fat mass in adulthood. 
(Spalding et al., 2008). 
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Fat tissue is not all the same; its composition and effect vary from place to 
place in the body. As illustrated in Figure 4A, individuals with excess adipose 
concentrated in the hip and thigh areas (pear-shaped obesity) have a lower risk 
of obesity than individuals with excess adipose tissue concentrated in the 
abdominal area (apple-shaped obesity) (Gesta et al., 2007). These types of 
tissue are referred to by their depth and superficiality: subcutaneous and visceral. 
Large amounts of abdominal and visceral fat are associated with increased waist 
circumference. Waist circumference is an important measure of obesity. In fact, 
several studies have shown that waist circumference explains obesity related 
health risks independent of BMI (Janssen et al., 2004). 
 
 
Figure 4A. Fat distribution influences risks associated with obesity in humans. 
(Gesta et al., 2007). 
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One hypothesis for the different health risks of subcutaneous fat and 
visceral fat is that different depots have unique innervations and relationships 
with circulation. For example, visceral fat may have increased lipolytic rates and 
release free fatty acids into the portal circulation. However, the leading 
hypothesis is that cell-autonomous mechanisms dictate depot-specific difference 
in adipocyte physiology. (Rosen and Spiegelman, 2014).  
Besides differences in fat location, there are two different types of adipose 
tissue: white (WAT) and brown (BAT). As seen in Figure 4B, BAT is often found 
in the interscapular, cervical, supraclavicular, and paravertebral areas. In 
contrast, WAT is located in the subcutaneous, intra-abdominal, and other areas. 
(Gesta et al., 2007). 
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Figure 4B. Fat distribution influences risks associated with obesity in humans. 
(Gesta et al., 2007). 
 
WAT is an energy storage tissue and it is the primary site of triglyceride 
storage. BAT, on the other hand, is an energy expenditure organ. BAT consumes 
energy via non-shivering thermogenesis.  High expression of uncoupling protein 
1 (UCP1) in mitochondria generates heat through the reduction of the proton 
gradient created by oxidative phosphorylation in cellular respiration. (Gesta et al., 
2007). 
BAT is the main source of heat for infants and some small mammals. Until 
recently, it was uncertain if adult humans had BAT and if BAT had any 
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physiologic relevance. BAT has been detected in adults with the assistance of 
radioactively labeled glucose and positron emission tomography (PET) and 
computed tomography (CT) (Cypess et al., 2009). It is now known that the 
amount of BAT in adults is inversely correlated to BMI, suggesting a role in 
preventing obesity (Cypess et al., 2009). The impact of BAT on energy 
homeostasis has massive implications, especially towards combating obesity. 
Research is focused on uncovering BAT lineage and differentiation in order to 
create a therapeutic application.  
Adipose is thought to share an embryonic origin with bone and muscle in 
mesenchymal and mesodermal stem cells. It was thought that WAT and BAT 
shared a common adipoblast precursor. (Gesta et al., 2007).  It is now 
recognized that BAT shares lineages with both WAT and skeletal muscle 
precursors. (Seale et al., 2008).  
The establishment of separate lineages has led to the classification of a 
new type of adipose, beige adipose tissue.  WAT contains cells that express 
UCP1 and are called beige or brite cells. These cells have distinct genetic 
expression patterns from BAT or WAT cells (Wu et al., 2012). During chronic 
exercise, muscle cells secrete irisin, a hormone that contributes to the “browning” 
or conversion of WAT to beige adipose tissue (Wu and Spiegelman, 2014). 
UCP1 mediated thermogenesis in BAT and beige adipose is mostly 
activated by cold exposure (Ye et al., 2013).  When peripheral neurons sense 
cold, the hypothalamus increases sympathetic activity. Norepinephrine turns on 
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β-adrenergic (G-protein coupled) receptors and a cyclic adenosine 
monophosphate (cAMP) cascade. Transcription of thermogenic genes are 
controlled by cAMP. It has also been shown that beige adipocytes respond 
directly to temperature (Ye et al., 2013). Further supporting the importance of 
these thermogenic adipose tissues, animal models demonstrate that lack of 
either BAT or beige adipose leads to obesity, insulin resistance, and metabolic 
dysfunction (Cohen et al., 2014). 
To maintain a healthy weight, it is important to have adequate amounts of 
both WAT and BAT. Not only does WAT store lipids, it also modulates 
metabolism as an endocrine, paracrine, and autocrine organ. It releases a 
number of hormones and cytokines, collectively referred to as adipokines 
(Khandekar et al., 2011). 
Leptin is a WAT hormone that regulates appetite and satiety. The leptin 
melancortin pathway in the hypothalamus suppresses appetite. Congenital leptin 
deficiency in humans is extremely rare. In the few reported cases, there was 
hyperphagia and early onset obesity. Limited studies show that leptin is more 
important for energy intake than energy expenditure in humans. Treatment of 
leptin deficiency with recombinant leptin leads to sustained weight loss (Farooqi 
et al., 1999). Obese (ob/ob) and diabetic (db/db) mice are commonly studied with 
leptin and its receptor knocked out, respectively. Leptin levels correlate well with 
body fat mass. Obese individuals without suppressed appetites, despite high 
levels of leptin, have leptin resistance. Leptin’s role outside of satiety continues to 
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be a research focus. (Coll et al, 2007).  
Adiponectin is another WAT hormone that is widely studied. Adiponectin is 
involved in glucose and fatty acid oxidation. It also has a strong correlation with 
insulin sensitivity. Adiponectin is found at a relatively higher order of 
concentration compared to other hormones. Unlike leptin, adiponectin is found at 
lower levels in obese individuals than in healthy individuals. (Coll et al., 2007). 
 
Other Tissues 
 The liver plays a central role in systemic metabolism. It is the site of 
glycogen synthesis and gluconeogenesis. In obesity, high blood sugars reflect 
excess hepatic glucose production due to insulin resistance. There is a decrease 
in clearance of lipoprotein, but synthesis of fatty acids and triglycerides still 
occurs. (Rask-Madsen and Kahn, 2012).  
Skeletal muscle has one of the largest impacts on energy homeostasis in 
humans. It is the main insulin sensitive organ in glucose uptake and disposal. 
Glucose is utilized for glycolysis for energy expenditure and glycogen synthesis. 
Through skeletal muscles, physical activity is a major component of energy 
expenditure. Sedentary lifestyles are often cited as a contributing factor to 
obesity. Insulin resistance leads to impaired glucose uptake and glycogen 
synthesis. Excess blood sugar leads to increased obesity and adiposity where 
glucose uptake for triglyceride synthesis is not affected as much. (Rask-Madsen 
and Kahn, 2012). 
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The pancreas is an exocrine gland and an endocrine gland. As an 
exocrine gland, it secretes digestive enzymes and bicarbonate into the digestive 
tract. As an endocrine gland, the islets of Langerhans are responsible for 
secreting insulin, glucagon, somatostatin, and pancreatic polypeptide. In obesity, 
insulin secretion in islet β-cells is progressively impaired, but glucagon levels 
remain high and glycogenolysis and gluconeogenesis are promoted. (Jin and 
Patti, 2009). 
Contributions to appetite and satiety are mainly mitigated by hormones 
such as leptin. However, evidence shows that insulin also plays a role. 
Hypothalamic insulin resistance leads to a decrease in the vagal nerve’s ability to 
suppress hepatic glucose production. (Rask-Madsen and Kahn, 2012). 
The digestive system also contributes to metabolism, affecting insulin 
secretion, appetite, and motility. Incretins such as glucagon-like peptide 1 (GLP-
1) and gastric inhibitory polypeptide (GIP) stimulate β-cell secretion of insulin in 
response to ingestion of food. Incretin secretion and sensitivity is impaired in 
obesity and T2DM. Evidence also points to bile acids as signaling molecules that 
influence metabolism (Watanabe, 2006). In addition, cholecystokinin is a 
postprandial satiety signal and ghrelin is a hunger hormone produced by the gut 
(Coll et al., 2007). 
Recently, the pathogenesis of MS and T2DM has been linked to 
inflammation (Shoelson et al., 2006).. Adipokines such as tumor necrosis factor α 
(TNF α) and interleukins such as interleukin 6 (IL6) have been shown to induce 
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insulin resistance. TNF α and IL6 are both readily produced by adipocytes and 
macrophages. Obesity is strongly correlated with acute and systemic 
inflammation in fat, liver, and the cardiovascular system (Shoelson et al., 2006). 
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INTERGENERATIONAL PROGRAMMING 
 
 
 
Heredity customarily refers to the transmission of traits from parents to 
children. Due to inheritance, children acquire characteristics that predispose 
them to certain phenotypes. Mendelian genetics explains inheritance through the 
transfer of the genome in the form of deoxyribonucleic acid (DNA). Most 
diseases have multifactorial inheritance patterns; they are rarely caused by a 
single gene, but rather caused by the culmination of numerous disturbances in 
gene expression. 
Intergenerational or trans-generational programming encompasses all 
aspects in which the parent or previous generations affect the offspring. Not all 
differences in phenotype are determined by genetic sequence. Environmental 
factors play a key role in the development of a child and obesity. People may 
form adaptations to environmental disruptions. Cumulative adaptations may then 
lead to a stable disease state. This process, in which events in early life impact 
long-term health, is called metabolic imprinting (Waterland and Garza, 1999). 
Crucial stages of development range from prenatal to adolescent. The strongest 
correlations of intergenerational programming are between parent and offspring. 
Parental obesity is strongly associated with adiposity in offspring. This 
predisposition may be caused by genetics or a number of other influences. The 
parental state may be “programming” the offspring into a similar metabolic 
condition. The correlation between offspring and maternal weight is markedly 
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higher than paternal weight, although still significant for paternal weight (Whitaker 
et al., 2010). The trend of parent to offspring adiposity holds for an individual 
parent, but is even stronger if both parents are obese. Figure 5 depicts the 
association of childhood obesity to each parent’s weight status. 
 
 
 
Figure 5. Frequency of child obesity by parental weight status. Normal weight 
BMI <25, overweight BMI 25-29.9, obese BMI 30-34.9, severe obese BMI ≥35. 
n= 7078. (Whitaker et al., 2010). 
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Parental Behavior 
Parents have an influence over their children’s behavior. At a young age, 
children may observe and mimic their parents’ poor eating habits and sedentary 
lifestyles. Childhood weight gain is usually predictive of a person’s body size later 
in life. Therefore, many studies are testing interventions to reduce the risk of 
children becoming obese like their parents. The behavior of parents is often a 
primary target in preventing and combating childhood obesity. Examples of such 
interventions include feeding infants nutritionally balanced food and reducing the 
amount of time parents allow children to spend doing sedentary activities such as 
watching television. (Campbell et al., 2013). 
 
Socioeconomic Status 
One of the challenges in preventing and combating childhood obesity is 
that all too often obese children come from families with limited economic 
resources. Obesity disproportionally affects disenfranchised communities. Food 
security is a measure of the accessibility of food. The USDA reports on food 
security in U.S. households (USDA, Economic Research Service, Food Security 
in the US). Low income populations typically have low food security. According to 
the USDA, 42% of households in the United States that are below the federal 
poverty line have food insecurity (Seligman and Schillinger, 2010). 
Low income populations are particularly vulnerable to the challenges of 
obesity due to food insecurity. They often have poor diets because nutritious food 
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is limited. These populations have fewer resources to allocate towards food and 
often invest in less expensive energy dense foods. These foods tend to be 
processed, refined, and high in added sugars, fats, and sodium.  
 Further exacerbating this problem is the fact that the difference in price 
between unhealthy food and healthy food is widening.  Between 1985 and 2000, 
the price of fresh fruits and vegetables rose 118% while fats and oils only rose 
35%. (Seligman and Schillinger, 2010).  
Besides socioeconomic status, food insecurity disproportionally affects 
certain races and education levels. Households with less education are linked to 
the consumption of fast foods. This is correlated to improper nutritional intake 
and excessive caloric intake (Meyer et al., 2014). Some minorities, such as 
African Americans and Hispanics, have a higher rate of food insecurity than white 
households (Seligman and Schillinger, 2010). Figure 6 displays the disparities in 
food security among different races in the United States.  
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Figure 6. Prevalence of food insecurity in the United States, 1999-2008. 
(Seligman and Schillinger, 2010). 
 
 
There is a higher incidence of obesity in children from low-income 
households of certain races (CDC, Overweight and Obesity, Data and Statistics). 
In 2008-2011, 11% of children from low-income households were found to be 
obese. When compared to non-Hispanic Caucasian children, Hispanic children 
had a 35% higher risk of obesity and American Indian/Alaskan Native children 
had a 49% higher risk of obesity. (Pan et al., 2013). 
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Extranueclear Inheritance 
The study of genetics places heavy emphasis on nuclear inheritance. 
Each parent passes half of their nuclear DNA through their gametes to their 
children. However, there is also extranuclear inheritance. The mother passes 
genetic information through the mitochondria in her oocytes. Mitochondria have 
their own DNA (mtDNA) and are important organelles involved in energy 
production, cell signaling, growth, differentiation, and apoptosis.  
The role of mtDNA in lipid and amino acid metabolism makes it a central 
component in risk for obesity on the cellular level (Sato and Sato, 2013).  In 
humans, the mitochondria in sperm enter the oocyte cytoplasm after fertilization, 
but the sperm’s mtDNA is eliminated and not transferred to the offspring (Sato 
and Sato, 2013). The paternal mtDNA is either diluted by a much larger amount 
of maternal mtDNA or it is selectively degraded. Therefore, this suggests that 
maternal mitochondrial inheritance has a stronger effect on progeny than 
paternal inheritance. 
 
Mother’s Weight 
While genetic inheritance and socioeconomic factors contribute to 
adiposity in children, evidence suggests that the relationship between the 
environment and obesity in offspring is very strong (Gluckman et al., 2008). The 
intrauterine environment is especially important in nurturing and developing the 
child. Perturbations in intrauterine metabolism may cause long-term 
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consequences in a child’s health. Maternal obesity may lead to fetal over-
nutrition, which increases a child’s risk of obesity. Obese mothers are more likely 
to have high blood glucose, free fatty acids, and amino acids. These high levels 
may alter the neuroendocrine function and energy metabolism in the developing 
fetus (Lawlor et al, 2007).  
Prospective longitudinal studies have aimed to determine the effects of 
weight gain during gestation on the offspring’s risk for obesity. A mother’s high 
pre-conception weight is a strong predictor of offspring obesity and 
cardiovascular risk (Fraser et al., 2010).  Similarly, high maternal gestational 
weight gain (GWG) is correlated with offspring who have a higher BMI, waist 
circumference, fat mass, leptin and other adipokine levels, systolic blood 
pressure, and lower HDL levels (Fraser et al., 2010). The effect is heightened 
from early pregnancy to 14 weeks gestation.  The United States Institute of 
Medicine suggests that healthy GWG is 500 grams per week. Pre-pregnancy 
BMI remains a stronger predictor of offspring risk and has a larger relative effect 
compared to GWG (Fraser et al., 2010). Nevertheless, both associations suggest 
harm from excess maternal adiposity through transmittance of genetics, weight 
gain promoting lifestyles, and environment to offspring (Fraser et al., 2010). 
 
Placenta 
The placenta plays a critical role in fetal development through nutrient 
delivery and waste removal. While the placenta originates from the maturing 
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blastocyst and shared parental genetic material, it is heavily influenced by the 
mother’s metabolic state upon implantation into the endometrium and throughout 
pregnancy. Maternal obesity causes placental lipotoxicity, which features 
increased oxidative stress and inflammation. It has also been shown to cause 
alterations in gene expression in angiogenesis, hormone activity, and cytokines. 
(Saben et al., 2014). 
Animal studies also show that a mother’s obesity or diet may change 
placenta and nutrient delivery. High sugar and high fat diets (HFD) during 
pregnancy increases maternal adiposity and reduces fetal placental growth. 
Affected placentas showed increased glucose and amino acid transport as well 
as up-regulation of fatty acid transport, PI3K, MAPK, and growth pathways 
(Sferruzzi-Perri et al., 2013). These changes have significant ramifications on 
offspring growth and health and are likely components in an offspring’s future 
metabolic dysfunction and cardiovascular dysfunction. 
 
Maternal Stress and Diet 
A mother’s diet can also affect the metabolism of offspring. Maternal HFD 
during gestation leads to poor glycemic control in offspring and increased risk of 
T2DM (Ainge et al., 2011). Researchers found that either stress or maternal HFD 
during gestation may promote predisposition to adiposity. In an animal model, 
pregnant Sprague-Dawley rats were given either control chow or a HFD. Variable 
stress was administered during gestation through a combination of restraint, 
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swimming, and cold exposure. Pups from dams that were on a HFD, 
administered stress, or both were heavier. They were also more likely to have 
increased adiposity and impaired glucose tolerance when weaned onto high fat 
diets (Tamashiro et al., 2009).  
In a subsequent study, it was shown that the early postnatal period might 
be more crucial in determining the metabolic phenotype of offspring than the 
prenatal period (Sun et al., 2012). Dams were fed either control chow or a HFD 
during both gestation and nursing. A cross fostering model, generating four 
groups, was used to compare the relative effects of the postnatal nursing period 
to gestation. Pups cross fostered to the HFD dams gained more body weight and 
adiposity, had higher leptin levels, had higher impaired glucose tolerance, and 
were hyperphagic after weaning when compared to pups fostered to control 
chow dams (Sun et al., 2012). 
 
Maternal Insulin Resistance 
 
In addition, other metabolic phenotypes have been characterized to have 
similar effects on offspring. Both maternal T2DM and GDM have been associated 
with greater offspring adiposity independent of maternal BMI in early pregnancy. 
These correlations held when comparing siblings that experienced maternal 
diabetes and those that did not, suggesting intrauterine mechanisms play a 
bigger role than shared familial characteristics like genetics and lifestyle (Lawlor 
et al., 2011).  
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Many experimental models share maternal characteristics of metabolic 
dysregulation. It is difficult to discern whether individual aspects or a combination 
of factors are responsible for amplifying offspring risk. In a mouse model of 
maternal insulin resistance, offspring were hyperinsulinemic, glucose intolerant, 
and had dysregulated lipid metabolism. The offspring became insulin resistant 
when fed a HFD. These changes occurred despite normal maternal blood 
glucose and body weight, demonstrating that maternal insulin resistance alone 
may program obesity risk in offspring. (Isganaitis et al., 2014).  
 
Intrauterine Growth Restriction 
Perhaps more striking than prenatal overnutrition may be prenatal 
undernutrition in terms of developmental programming of obesity risk. 
Intrauterine growth restriction (IUGR) may occur from placental insufficiency, 
suboptimal perfusion, or maternal malnourishment.  
IUGR often leads to low birth weight (LBW) in children. Both human and 
animal studies have shown that LBW is associated with increased risk of obesity, 
MS, T2DM, and CVD (Gluckman et al., 2008). A widely accepted theory is that 
nutritional disruptions and other challenges during growth are met with 
developmental plasticity. Adaptation permits survival in an environment that is 
predicted by this challenge.  In IUGR, the predicted environment is scarce and 
deficient of resources. For example, increase adiposity as storage when there 
are not enough energy supplies or decrease efficiency in expenditure in order to 
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conserve energy. Alterations such as these may persist into adulthood and 
manifest into higher risk of diseases, including obesity and T2DM. (Gluckman et 
al., 2008). IUGR caused by decreased fetal placental perfusion has been found 
to lead to cardiovascular adaptations in offspring, increasing risk for CVD 
(Gaillard et al., 2013). 
 
Maternal Undernutrition 
 Undernutrition negatively affects offspring. Animal studies have shown 
that metabolic programming begins very early. A common model of IUGR or 
undernutrition is food restriction during gestation to simulate maternal 
malnourishment. Additionally, some models use synthetic glucocorticoid 
administration. Glucocorticoids have anti-inflammatory and immunosuppressant 
effects and are released in response to stress. High levels of maternal 
glucocorticoids are linked to abnormal pancreatic islet development in offspring. 
Beta cell growth is retarded and insufficiency of the resultant endocrine pancreas 
causes disruption of glucose homeostasis. (Somm et al., 2012). 
 In a model used by Somm et al., Sprague Dawley rats were restricted to 
30% of normal food intake throughout gestation. A parallel synthetic 
glucocorticoid model was also run. Dexamethasone was infused via pump during 
the last week of gestation. Postnatally, all groups were treated the same and 
dams were allowed to eat ad libitum. Both groups of LBW pups were 
hyperglycemic, had decreased glucose tolerance, and had reduced islet size and 
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numbers. Additionally there was upregulation and expression of hepatic 
gluconeogenesis, decreased insulin sensitivity, and changes in pancreatic and 
adipose gene expression. These results were found before weaning and while 
the LBW pups still weighed less than control. The findings are consistent with 
early metabolic dysregulation and could provide the basis of fetal programming 
leading to obesity and other complications in later life. (Somm et al., 2012). 
Accelerated growth typically occurs postnatally in early stages of life. This 
phenomenon is referred to as “catch-up growth.” When coupled with IUGR, high 
growth rates tend to overcompensate and LBW offspring become heavier than 
their normal weight counterparts. Extra acquired weight is often in the form of 
adiposity.  
In a mouse model of prenatal undernutrition, ICR mice exposed to 50% 
food restriction during the third week of gestation were born with LBW (Jiménez-
Chillarón et al., 2006). Similar to human populations, mice exposed to prenatal 
undernutrition developed increased adiposity.  In ICR mice, increased adiposity 
is found in visceral gonadal fat tissue. Interestingly, this has been found to be 
caused by lipogenesis and not by adipogenesis. Although adipocyte number 
does not increase, adipocyte diameter and lipogenic gene expression does 
increase (Jiménez-Chillarón et al., 2006). mtDNA copy number is also reduced 
(Isganaitis et al., 2009). Consequently, obesity may occur as early as 2 months 
both in humans and mice. This altered trajectory in growth parallels higher rates 
of MS, T2DM, and CVD. Intervention to mitigate catch-up growth may be 
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achieved by early postnatal caloric reduction. This restriction also prevents 
glucose intolerance and obesity (Jiménez-Chillarón et al., 2006). 
A possible explanation as to why undernutrition causes increased 
offspring adiposity is disruption in leptin signaling. An unexpected rise in leptin is 
observed in the neonatal period of mice exposed to undernutrition. Researchers 
found that offspring that had normal intrauterine nutrition but administered leptin 
in early age had an accelerated weight gain with HFD. This group on normal 
chow also had impaired leptin resistance, similar to undernutrition mice. Also, 
leptin transport in the brain was diminished. These finding suggest that 
premature leptin surge leads to leptin resistance and is a contributing factor 
towards obesity. (Yura et al., 2005). 
A new direction in the field of developmental programming is studying how 
effects may be passed on to subsequent generations beyond just immediate 
offspring. LBW offspring have been documented to have LBW children, even 
without further environmental stress, both in humans and mice (Patti, 2013a). At 
the Joslin Diabetes Center, researchers have developed an intergenerational 
IUGR LBW model using caloric restriction in ICR mice. In order to determine if 
programmed risk has an effect on multiple generations, LBW offspring were 
intercrossed with control offspring. Undernutrition was implemented with 50% 
caloric restriction in the final week of gestation. Second generation crossings 
were done with no dietary or stress manipulations. Experimental groups in these 
crossings did not differ in blood glucose, triglycerides, free fatty acids, insulin or 
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leptin levels. Nevertheless, second generation offspring through LBW males 
were found to have statistically significant reductions in birth weight. Second 
generation offspring through LBW females had increased adiposity in the form of 
visceral fat. Impaired glucose tolerance and pancreatic islet function was 
transmitted through both lineages. (Jiménez-Chillarón et al., 2009). 
It is unknown which intergenerational transmission of risk mechanisms 
has the strongest influence on offspring. As summarized in Table 2, maternal and 
paternal contributions share equal parts in some but not all processes; some 
processes have gender specific impact from parent to offspring. Additional 
studies are required to further characterize each effect. 
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Table 2. Potential mediators of maternal and paternal intergenerational 
phenotypic transmission. (Adapted from Patti, 2013a). 
 
INTERGENERATIONAL EFFECTS Maternally Mediated 
Paternally 
Mediated 
Postnatal environment (diet, stress, socioeconomic 
factors)   
Genetics (nuclear DNA sequence)   
Mitochondrial DNA   
Placental structure/function   
Intrauterine and early postnatal environment 
(dysregulation of maternal nutrition or metabolism, 
altered uterine structure/function, maternal 
behavior, alterations in maternal nursing behavior 
or milk composition) 
 
 
Germ cell epigenetic effects (nuclear and cytosolic)   
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EPIGENETICS 
  
 
 
An emerging concept is the science of epigenetics. This relatively new 
field has grown dramatically in recent years. Epigenetics is loosely defined as the 
study of the heritable changes of gene regulation and expression not caused by 
mutations or changes in DNA sequences.  
 Until recently, it was unknown how intergenerational metabolic risk was 
transmitted. In female offspring, oogenesis begins in the fetus and oocytes are 
completely developed at birth; thus the second-generation offspring is affected 
during the first generation’s pregnancy. Studies have shown that the health of a 
parent can negatively affect the metabolic outcomes of offspring beyond the 
second generation. Additional studies have shown that male lineages are also 
affected (Patti, 2013a). 
These trends, coupled with twin and adoption studies, suggest that there 
is an influence on metabolic fates beyond genetics and the immediate 
environment. Epigenetics provides a viable avenue for mechanistic explanations 
of intergenerational programming. An adaptive epigenetic model provides 
support to a stable and reversible theory of metabolic plasticity (Gluckman et al., 
2008). 
Two classic examples of epigenetics are DNA methylation and chromatin-
related proteins that activate and suppress transcription. Polycomb and trithorax 
protein systems work to maintain gene transcription and expression in both 
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silenced and active states (Bird, 2007). These protein systems often function 
through modulating chromatin remodeling as well as binding directly to DNA. 
Chromatin remodeling such as histone modifications is also now included in 
epigenetics. Even though certain chromatin marks (i.e. phosphorylation) may be 
transitory and therefore may or may not be heritable, they do indirectly affect 
acetylation, methylation, and repressor proteins (Bird, 2007). 
Lately, epigenetics has further expanded to also include noncoding RNAs 
such as microRNAs (miRNA). Even though the majority of the genome is 
transcribed, only a small proportion is translated into protein. Noncoding RNAs 
are the short strands of RNA that are not translated. They can act with repressor 
protein complexes to suppress gene expression. miRNAs can also bind to 
messenger RNA (mRNA) and inhibit translation of target genes. They also play a 
role in RNA-induced silencing complexes. (Tammen et al., 2013). 
 
Epigenetic Mechanisms 
 There are several distinctive mechanisms of epigenetics. The most 
studied epigenetic mark and process is DNA methylation. Methylation occurs 
most frequently on cytosines at the 5’ position. Cytosines followed by guanine 
(connected by a phosphodiester bond) in the genomic sequence are 
preferentially methylated. Regions are commonly referred to as CpG islands 
when there is a high frequency of these repeats. Recent reports have found 
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methylation outside of these areas, but most epigenetic studies focus on the 
nearly 30 million CpG sequences in our genome. (Tammen et al., 2013).  
 
 
Figure 7. Major epigenetic mechanisms: DNA methylation, histone modifications, 
and noncoding RNAs. (Milagro et al., 2013). 
 
DNA methytransferases methylate cytosines with donated methyl groups 
from adenosylmethionine. Methylation found in gene promoters is usually 
associated with repression and down regulation. While the mechanism of action 
is not completely understood, recruitment of inhibitory proteins can prevent 
transcription and consequently adjust expression patterns. Hydroxymethylation is 
usually associated with the up regulation of genes. Hydroxymethlated cytosines 
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are sometimes considered as intermediates in de-methylation or as mediators 
that release the methyl-binding proteins. Maintenance and the removal or 
generation of marks is associated with age and disease (Tammen et al., 2013). 
 One of the most characterized models of reversible methylation is the 
agouti mouse (Jirtle and Skinner, 2007). The agouti gene encodes for a signaling 
molecule that promotes yellow pigment production in melanocytes. Expression of 
agouti in other tissues besides the skin leads to obesity, T2DM, and 
tumorgenesis. Methylation of a locus upstream of the transcriptional start site 
inhibits expression. This was the first model to show how the maternal diet can 
affect offspring adult phenotype through methylation.  Dietary supplementation of 
methyl-donors to mothers during pregnancy decreased agouti expression in 
offspring. Figure 8 shows the progressive distribution of phenotype. Offspring are 
raised in the same environment with no difference in diet or environment except 
maternal exposure during gestation. Low methylation leads to an obese mouse 
with yellow fur and high methylation leads to a leaner mouse with brown fur. 
(Jirtle and Skinner, 2007). 
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Figure 8. Epigenetic regulation in agouti mice. Genetically identical week 15 
Avy/a mice with different levels of methylation. (Jirtle and Skinner, 2007). 
 
 
The other main class of epigenetics is histone modifications and chromatin 
remodeling. Histones participate in structuring chromatin by packaging DNA. 
They can be modified post-translationally via acetylation, phosphorylation, 
methylation, ubiquitination, biotinylation, ADP-ribosylation, and sumoylation. 
Many of these modifications occur on the histone tails. Some of the modifications 
will recruit repressor proteins similar to DNA methylation mechanisms, while 
some will influence ionic charge. In turn, the interaction between the histones and 
the bound DNA is altered. The state of DNA packaging determines the state of 
heterochromatin and euchromatin. Gene expression is increased or decreased 
based on spatial constraints for transcription factors and ribonucleic acid (RNA) 
polymerases. (Tammen et al., 2013). 
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Observations in Intergenerational Programming 
 Epigenetics as a process that is involved in intergenerational programming 
is gaining more support. Many investigators in the field of developmental 
programming are testing the hypothesis that alterations in epigenetic marks, such 
as DNA methylation, may contribute to the intergenerational transmission of 
metabolic traits (Patti, 2013b). Strong associations with changes in the 
epigenome or total epigenetic state could help elucidate the underlying etiology 
of disease. At the very least, significant associations would provide biomarkers 
and predictors of susceptibility to disease. 
 The most common approach of initial epigenetic research into 
intergenerational programming has been manipulations of diet. Nutrition is one of 
the easier controlled environmental factors.  Experimental design has included 
HFD, overfeeding, low protein diets, and caloric restriction both during IUGR and 
during critical periods of development postnatally (Jiménez-Chillarón et al., 
2012). Another focal point of diet modification is supplementation of methyl-
donors. Folic acid has been the most popular chosen micronutrient. Others 
include choline, betaine, B vitamins, and methionine. (Anderson et al., 2012). 
 Other models of intergenerational and epigenetic study include paternal 
stresses. Male mice fed a HFD have offspring with dysregulation of hepatic 
cholesterol and lipid metabolism and reproducible changes in epigenetic profiles 
(Carone et al., 2010). In a similar study, males with prediabetes had offspring 
with glucose intolerance and insulin resistance. Methylation of paternal sperm 
 61 
corresponded to altered pancreatic gene expression in offspring. (Wei et al., 
2014). 
Similar to maternal models, paternal epigenetic transmission can persist 
through multiple generations. One study found that diet induced obesity in males 
caused two subsequent generations to have increased adiposity and insulin 
resistance (Fullston et al., 2013). These phenotypes developed in subsequent 
generations under normal diet and environment. Changes in the gene expression 
and miRNA profiles of the original males were found in testis and sperm (Fullston 
et al., 2013). Collectively, these studies implicate paternal contributions in 
intergenerational programming via epigenetics. 
 One of the challenges that come with epigenetic studies is that these 
alterations occur in all systems of the body. Given that our complex metabolism 
incorporates so many tissue types, it is important to examine changes in each. In 
order to determine cell specific roles, it is essential to compare methylation 
patterns between them to find differences. Epigenetic signatures of differentially 
methylated sites as a whole can be used as predictors for disease. Under 
multiple models of maternal IUGR and paternal stress, reproducible epigenetic 
signatures have been found to be associated with nutritional history. (Colaneri et 
al., 2013). 
 Far less data has been published on humans than animals.  Ethical 
constraints prevent easy tissue sampling for epigenetic mark testing. However, 
early returns are encouraging and imply that results do translate over. 
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Associations have been established between gene promoter methylation in 
umbilical cord tissue with childhood adiposity (Godfrey et al., 2011). Differential 
methylation of cord blood and placental tissue has also been found between 
mothers with insulin-dependent GDM compared to those without (El Hajj et al., 
2013). 
 Initial studies on weight loss have also suggested epigenetic processes as 
a possible mechanism of metabolic programming. Differences in adipose 
methylation comparing before and after a 6 month exercise intervention 
highlighted genes involved in oxidative phosphorylation. Expression is typically 
lower in obese or elderly individuals (Rönn et al., 2014). Differential methylation 
has also been found in offspring born before and after maternal bariatric surgery 
and weight loss. Reduced maternal weights lead to offspring who are less obese 
and have lower metabolic risk. Patterns in methylation correlated with expression 
of genes associated with glucose regulation, inflammation, and vascular disease. 
(Guénard et al., 2013). 
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DISCUSSION 
  
 
 
Obesity, along with its associated comorbidities, is becoming one of the 
most significant health problems of our generation. Despite the wealth of 
information that is known about risk, prevention, and treatment, obesity continues 
to become more and more prevalent. Preventing obesity has been shown to be 
more cost-effective than treating its complications (Fradkin et al., 2012). The 
approach to fighting obesity may need to be revitalized with new initiatives to 
bring more awareness to the general public. Organizations, like the AMA, have 
been reluctant to take strong public stances on obesity until now. Hopefully, the 
added attention to obesity awareness and prevention will reach policy makers, 
insurance companies, and the general public to reduce this public health 
epidemic. 
Long term goals should focus on further characterizing obesity’s various 
risks and causes. Although there is overall optimism in obesity prevention in 
children since the overall rates have recently leveled off, the incidence has also 
been occurring at earlier ages (Cunningham et al., 2014). This emphasizes the 
impact of metabolic programming and environmental stresses during early 
development. Perhaps obesity may not be prevented with only diet and exercise; 
there may be additional factors that are outside of one’s control.  
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Genetics has long been recognized as a contributor to human metabolism. 
Parental and earlier generational phenotypes have also been shown to affect 
genetic expression patterns of offspring.  
Understanding the contribution of intergenerational programming and 
epigenetics will provide a strong basis for obesity prevention and treatment. 
Evidence already suggests that epigenetics has a strong impact on health. 
Questions remain about whether epigenetic signatures are a possible 
mechanism of causation or merely a correlation. Epigenetic profiles still can 
serve as early predictors of the developmental origins of disease and assist in 
discerning predisposition in future generations.  
 There are a number of challenges that make progress in these fields 
difficult. Changes in epigenetic marks are on a miniscule scale. The impact of 
environmental stresses and their consequent epigenetic changes are understood 
to be small and cumulative. The pathogenesis of obesity also seems to be 
caused by small cumulative changes. The multi-dimensional interactions of 
molecular signals create an incredibly complex network. Evaluating each change 
and its relative contribution is a daunting task. 
 Furthermore, methods of detection of epigenetic change are numerous. 
The field of epigenetics has expanded to include many different alterations from 
DNA methylation to histone modification to RNA expression. Early research in 
epigenetics has featured many different methods of measurement. There is no 
universal standard of assessing the overall epigenome. 
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Many researchers choose to focus on CpG islands, where methylation is 
most prevalent. However, sometimes this fails to incorporate areas that are 
outside of these genomic regions where methylation still occurs. Others choose 
to do genome wide epigenetic studies. These are more general and search for 
consistent differences between experimental groups. Differential studies in tissue 
specific methylation attempt to define the individual contributions of different 
cells. The caveat here is that individuals are very different, even within the same 
category or experimental group. For example, not all patients with the same BMI 
have the same health outcome. Obesity and metabolic disease are continuums; 
it is impossible to categorize severity with arbitrary benchmarks. Small changes 
in epigenetic marks may be easily overlooked. Furthermore, histone 
modifications are so diverse and seldom studied, that it is a challenge to compile 
and compare studies. It is still unknown which marks are more influential on 
phenotype. 
It is important to study epigenetic marks and their modulation of gene 
expression to determine their effect on molecular, cellular, and systemic 
development. This field continues to progress and more accurate methods of 
measurement will be developed. 
Alterations in epigenetic patterns have been strongly linked to both obesity 
and weight loss. Discovering how to influence epigenetic changes could unveil 
potential therapeutic targets. It will also aid researchers in the development of 
better prevention and treatment strategies. Epigenetic patterns can be applied to 
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the analysis of existing treatments. Comparison of epigenetic profiles in healthy 
versus unhealthy individuals, as well as successfully and unsuccessfully treated 
patients, could provide a measure of efficacy. Results may help us better assess 
the risks and benefits of different strategies. 
One of the most debated weight management approaches is bariatric 
surgery. Given the recent emphasis on metabolic programming, there is interest 
on the effect of maternal bariatric surgery on offspring. Some studies have found 
that these operations significantly increase the chances of a preterm delivery. 
Infants of these mothers were also more likely to be small for their gestational 
age. This may be caused by poor nutrient absorption after bariatric surgery 
(Roos et al., 2013).  
However, others have shown that maternal bariatric surgery actually 
improves offspring metabolism and it changes methylation patterns (Guénard et 
al., 2013). It is difficult to compare among recent studies because there are not 
very many and the populations vary so widely in age, genetics, environment, 
lifestyle, and weight loss. There may also be a metabolically unstable period after 
surgery that is suboptimal for pregnancy. It is important to determine which 
changes affect which outcomes. Nevertheless, optimism remains that these 
research studies will eventually pave the way in reducing maternal obesity and 
preventing offspring risk (Patti, 2013b). 
Overall, future directions should include large-scale prospective studies. 
Longitudinal research will allow us to study epigenetics, disease, age, and 
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intergenerational transmission of risk and how they are affected by each other. It 
will be interesting to see how far intergenerational programming can go and if risk 
can be mitigated.  
Both animal and human studies are needed. Animal studies are less 
expensive, can be done on a larger scale, are easier to control for variation, and 
provide more opportunities ethically. At the same time, findings in animal studies 
face limitations in translation and application to human disease. 
In conclusion, although obesity is so prevalent in modern society, much 
remains unknown about its causes. It is hoped that by further studying the 
epigenetics and intergenerational transmission of risk of obesity, a cure and 
infallible method of prevention will be discovered.  
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